Literature DB >> 28083597

[Psoriatic arthritis : Overview of drug therapy options and administration characteristics].

F Behrens1, D Thaçi2, J Wollenhaupt3, K Krüger4.   

Abstract

Psoriatic arthritis is a chronic inflammatory disease of the musculoskeletal system with association to skin psoriasis and is characterized by variable clinical symptoms with very heterogeneous degrees of disease suffering for patients. Clinical manifestations essentially include alterations to the skin and nails, peripheral arthritis, enthesitis, dactylitis and/or spinal involvement. This variability necessitates an individualized therapy of patients with different therapy targets. Apart from international guidelines no therapy recommendations are available in Germany for treatment of psoriatic arthritis. For this reason this article summarizes the established points, characteristics and aspects to be considered in the therapy of psoriatic arthritis in Germany, taking the various main forms of the disease into consideration.

Entities:  

Keywords:  Dactylitis; Disease activity; Enthesitis; Joints; Musculoskeletal system

Mesh:

Substances:

Year:  2017        PMID: 28083597     DOI: 10.1007/s00105-016-3925-9

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  53 in total

1.  Generalized pustular psoriasis induced by systemic glucocorticosteroids: four cases and recommendations for treatment.

Authors:  M Brenner; S Molin; K Ruebsam; P Weisenseel; T Ruzicka; J C Prinz
Journal:  Br J Dermatol       Date:  2009-06-11       Impact factor: 9.302

2.  Systemic steroids in the treatment of psoriasis: what is fact, what is fiction?

Authors:  U Mrowietz; S Domm
Journal:  J Eur Acad Dermatol Venereol       Date:  2012-07-25       Impact factor: 6.166

3.  Clinical manifestations and responsiveness to adalimumab are similar in patients with ankylosing spondylitis with and without concomitant psoriasis.

Authors:  Jürgen Braun; Martin Rudwaleit; Sonja Kary; Martina Kron; Robert L Wong; Hartmut Kupper
Journal:  Rheumatology (Oxford)       Date:  2010-05-06       Impact factor: 7.580

4.  The role of methotrexate co-medication in TNF-inhibitor treatment in patients with psoriatic arthritis: results from 440 patients included in the NOR-DMARD study.

Authors:  Karen Minde Fagerli; Elisabeth Lie; Désirée van der Heijde; Marte Schrumpf Heiberg; Ase Stavland Lexberg; Eric Rødevand; Synøve Kalstad; Knut Mikkelsen; Tore K Kvien
Journal:  Ann Rheum Dis       Date:  2013-01-03       Impact factor: 19.103

5.  A randomised, double blind, placebo controlled, multicentre trial of combination therapy with methotrexate plus ciclosporin in patients with active psoriatic arthritis.

Authors:  A D Fraser; A W R van Kuijk; R Westhovens; Z Karim; R Wakefield; A H Gerards; R Landewé; S D Steinfeld; P Emery; B A C Dijkmans; D J Veale
Journal:  Ann Rheum Dis       Date:  2004-11-04       Impact factor: 19.103

6.  Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial.

Authors:  Wolfram Sterry; Jean-Paul Ortonne; Bruce Kirkham; Olivier Brocq; Deborah Robertson; Ronald D Pedersen; Joanne Estojak; Charles T Molta; Bruce Freundlich
Journal:  BMJ       Date:  2010-02-02

7.  Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial.

Authors:  J Peter Kaltwasser; Peter Nash; Dafna Gladman; Cheryl F Rosen; Frank Behrens; Peter Jones; Jürgen Wollenhaupt; Franziska G Falk; Philip Mease
Journal:  Arthritis Rheum       Date:  2004-06

8.  Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy.

Authors:  Mark C Genovese; Philip J Mease; Glen T D Thomson; Alan J Kivitz; Renee J Perdok; Mark A Weinberg; John Medich; Eric H Sasso
Journal:  J Rheumatol       Date:  2007-04-15       Impact factor: 4.666

9.  Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND study.

Authors:  Asta Baranauskaite; Helena Raffayová; N V Kungurov; Anna Kubanova; Algirdas Venalis; Laszlo Helmle; Shankar Srinivasan; Evgeny Nasonov; Nathan Vastesaeger
Journal:  Ann Rheum Dis       Date:  2011-10-12       Impact factor: 19.103

10.  Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor.

Authors:  Arthur Kavanaugh; Philip J Mease; Juan J Gomez-Reino; Adewale O Adebajo; Jürgen Wollenhaupt; Dafna D Gladman; Eric Lespessailles; Stephen Hall; Marla Hochfeld; ChiaChi Hu; Douglas Hough; Randall M Stevens; Georg Schett
Journal:  Ann Rheum Dis       Date:  2014-03-04       Impact factor: 19.103

View more
  3 in total

Review 1.  [Psoriatic arthritis : Current therapeutic standards].

Authors:  M Köhm; F Behrens
Journal:  Z Rheumatol       Date:  2017-08       Impact factor: 1.372

Review 2.  [The skin and rheumatism].

Authors:  S Ständer; R J Ludwig; D Thaçi
Journal:  Orthopade       Date:  2019-11       Impact factor: 1.087

Review 3.  [Treatment of psoriatic arthritis : Are there differential indications?]

Authors:  M Köhm; F Behrens
Journal:  Z Rheumatol       Date:  2020-02       Impact factor: 1.372

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.